138 related articles for article (PubMed ID: 35482558)
1. Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT.
McLornan DP; Gras L; Martin I; Sirait T; Schroeder T; Blau IW; Kuball J; Byrne J; Collin M; Stadler M; Desmier D; Salmenniemi U; Jindra P; Mikhailova N; Lenhoff S; Rifón J; Robin M; Rovira M; Veelken H; Sadowska-Klasa A; Zecca M; Hayden PJ; Czerw T; Hernández-Boluda JC; Yakoub-Agha I
Br J Haematol; 2022 Jul; 198(1):209-213. PubMed ID: 35482558
[No Abstract] [Full Text] [Related]
2. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT.
Robin M; Gras L; Koster L; Gagelmann N; van Gorkom G; Ederr M; Itälä-Remes M; Zuckerman T; Beguin Y; Schaap N; Drozd-Sokolowska J; Raj K; Hayden PJ; de Wreede LC; Battipaglia G; Polverelli N; Czerw T; Hernandez Boluda JC; Kröger N; Yakoub-Agha I; McLornan DP
Br J Haematol; 2024 Feb; 204(2):715-718. PubMed ID: 38014808
[No Abstract] [Full Text] [Related]
3. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT.
Ringdén O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M;
Br J Haematol; 2017 Feb; 176(3):431-439. PubMed ID: 27879990
[TBL] [Abstract][Full Text] [Related]
4. Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of current literature.
Robin M; Gras L; Koster L; Saccardi R; Finke J; Forcade E; Rovira M; Kobbe G; Reményi P; Apperley J; Smaranda A; Bay JO; Casper J; de Wreede LC; Giebel S; Grillo G; Heras I; Potter V; Tischer J; Trociukas I; Nachbaur D; Drozd-Sokolowska J; Raj K; Gurnari C; Yakoub-Agha I; Onida F; Scheid C; McLornan D
Bone Marrow Transplant; 2023 Aug; 58(8):942-945. PubMed ID: 37185613
[No Abstract] [Full Text] [Related]
5. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
Aoudjhane M; Labopin M; Gorin NC; Shimoni A; Ruutu T; Kolb HJ; Frassoni F; Boiron JM; Yin JL; Finke J; Shouten H; Blaise D; Falda M; Fauser AA; Esteve J; Polge E; Slavin S; Niederwieser D; Nagler A; Rocha V;
Leukemia; 2005 Dec; 19(12):2304-12. PubMed ID: 16193083
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Shimoni A; Robin M; Iacobelli S; Beelen D; Mufti GJ; Ciceri F; Bethge W; Volin L; Blaise D; Ganser A; Luft T; Chevallier P; Schwerdtfeger R; Koster L; de Witte T; Kröger N; Nagler A; Yakoub-Agha I
Br J Haematol; 2021 Nov; 195(3):417-428. PubMed ID: 34514596
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Onida F; de Wreede LC; van Biezen A; Eikema DJ; Byrne JL; Iori AP; Schots R; Jungova A; Schetelig J; Finke J; Veelken H; Johansson JE; Craddock C; Stelljes M; Theobald M; Holler E; Schanz U; Schaap N; Bittenbring J; Olavarria E; Chalandon Y; Kröger N
Br J Haematol; 2017 Jun; 177(5):759-765. PubMed ID: 28369779
[TBL] [Abstract][Full Text] [Related]
8. Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies.
Tomaszewska A; Jagasia M; Beohou E; van der Werf S; Blaise D; Kanfer E; Milpied N; Reményi P; Ciceri F; Bourhis JH; Chevallier P; Solano C; Socié G; Bruno B; Rambaldi A; Castagna L; Kröger N; Corradini P; Afanasyev B; Ladetto M; Niederwieser D; Scheid C; Sengeloev H; Kroschinsky F; Yakoub-Agha I; Schoemans H; Koenecke C; Penack O; Perić Z; Greinix H; Duarte RF; Basak GW
Front Immunol; 2020; 11():613954. PubMed ID: 33603743
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.
McLornan DP; Hernandez-Boluda JC; Czerw T; Cross N; Joachim Deeg H; Ditschkowski M; Moonim MT; Polverelli N; Robin M; Aljurf M; Conneally E; Hayden P; Yakoub-Agha I
Leukemia; 2021 Sep; 35(9):2445-2459. PubMed ID: 34040148
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Poiré X; Labopin M; Maertens J; Yakoub-Agha I; Blaise D; Ifrah N; Socié G; Gedde-Dhal T; Schaap N; Cornelissen JJ; Vigouroux S; Sanz J; Michaux L; Esteve J; Mohty M; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):20. PubMed ID: 28100265
[TBL] [Abstract][Full Text] [Related]
11. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT.
Savani BN; Labopin M; Kröger N; Finke J; Ehninger G; Niederwieser D; Schwerdtfeger R; Bunjes D; Glass B; Socié G; Ljungman P; Craddock C; Baron F; Ciceri F; Gorin NC; Esteve J; Schmid C; Giebel S; Mohty M; Nagler A
Haematologica; 2016 Jun; 101(6):773-80. PubMed ID: 26969081
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT.
Koenecke C; Eikema DJ; Hazelaar S; Schroeder T; Potter V; Kröger N; Bornhäuser M; Finke J; Platzbecker U; Radujkovic A; Ganser A; Salmenniem U; Blaise D; Kobbe G; Meijer E; Friis L; Maertens J; Caballero D; Cornelissen JJ; Olivieri A; Gulsum O; Hayden PJ; Onida F; Robin M; Yakoub-Agha I
Bone Marrow Transplant; 2022 Oct; 57(10):1607-1611. PubMed ID: 35871086
[No Abstract] [Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
15. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT.
Gutiérrez-García G; Martínez C; Boumendil A; Finel H; Malladi R; Afanasyev B; Tsoulkani A; Wilson KMO; Bloor A; Nikoloudis M; Richardson D; López-Corral L; Castagna L; Cornelissen J; Giltat A; Collin M; Fanin R; Bonifazi F; Robinson S; Montoto S; Peggs KS; Sureda A
Br J Haematol; 2022 Feb; 196(4):1018-1030. PubMed ID: 34750806
[TBL] [Abstract][Full Text] [Related]
17. Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Eder S; Beohou E; Labopin M; Sanz J; Finke J; Arcese W; Or R; Bonifazi F; Aljurf M; Socié G; Passweg J; Giebel S; Mohty M; Nagler A
Am J Hematol; 2017 Jan; 92(1):18-22. PubMed ID: 27673280
[TBL] [Abstract][Full Text] [Related]
18. Association of uric acid levels before start of conditioning with mortality after allogeneic hematopoietic stem cell transplantation - a prospective, non-interventional study of the EBMT Transplant Complication Working Party.
Penack O; Peczynski C; van der Werf S; Finke J; Ganser A; Schoemans H; Pavlu J; Niittyvuopio R; Schroyens W; Kaynar L; Blau IW; van der Velden W; Sierra J; Cortelezzi A; Wulf G; Turlure P; Rovira M; Ozkurt Z; Pascual-Cascon MJ; Moreira MC; Clausen J; Greinix H; Duarte RF; Basak GW
Haematologica; 2020 Jul; 105(7):1977-1983. PubMed ID: 31601686
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
Drozd-Sokolowska J; Gras L; Zinger N; Zahrani MA; Passweg J; Byrne J; Ho A; Huang XJ; Kröger N; Mayer J; Russo D; De Becker A; Tbakhi A; Stamatoullas A; Valerius T; Hayden P; McLornan DP; Onida F; Scheid C; Robin M; Yakoub-Agha I
Bone Marrow Transplant; 2023 Feb; 58(2):222-225. PubMed ID: 36402922
[No Abstract] [Full Text] [Related]
20. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis.
Albert MH; Slatter MA; Gennery AR; Güngör T; Bakunina K; Markovitch B; Hazelaar S; Sirait T; Courteille V; Aiuti A; Aleinikova OV; Balashov D; Bernardo ME; Bodova I; Bruno B; Cavazzana M; Chiesa R; Fischer A; Hauck F; Ifversen M; Kałwak K; Klein C; Kulagin A; Kupesiz A; Kuskonmaz B; Lindemans CA; Locatelli F; Lum SH; Maschan A; Meisel R; Moshous D; Porta F; Sauer MG; Sedlacek P; Schulz A; Suarez F; Vallée TC; Winiarski JH; Zecca M; Neven B; Veys P; Lankester AC
Blood; 2022 Mar; 139(13):2066-2079. PubMed ID: 35100336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
